Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tenax Therapeutics ( (TENX) ) has provided an update.
On April 22, 2026, Tenax Therapeutics appointed veteran healthcare finance executive Thomas R. Staab, II as chief financial officer, effective May 11, 2026, succeeding interim CFO Thomas A. McGauley, who will remain in a consulting role through the filing of the company’s March 31, 2026 quarterly report and assist with the transition into late May. The move brings a seasoned public-company dealmaker and biotech finance specialist onto the leadership team as Tenax scales its global registrational program for levosimendan and positions TNX-103 as a potential first-in-class therapy for PH-HFpEF, with Staab’s compensation package anchored by inducement equity awards that align his incentives with long-term shareholder value.
Under Staab’s employment agreement, Tenax granted him 10,000 restricted stock units and options to purchase 450,000 shares, with multi-stage vesting schedules tied to his continued service. The company also structured tiered severance protections, including enhanced benefits in the event of a corporate transaction, underscoring both the strategic importance of the CFO role at this stage of Tenax’s development and the potential for future corporate or strategic activity in a competitive cardiopulmonary drug development landscape.
The most recent analyst rating on (TENX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Tenax Therapeutics stock, see the TENX Stock Forecast page.
Spark’s Take on TENX Stock
According to Spark, TipRanks’ AI Analyst, TENX is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, widening losses, and accelerating cash burn), which raises ongoing funding and dilution risk. Technicals are a meaningful positive with an established uptrend and positive momentum indicators, while valuation remains challenged due to negative earnings and no dividend yield data.
To see Spark’s full report on TENX stock, click here.
More about Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on novel cardiopulmonary therapies. The company holds global rights to develop and commercialize levosimendan, including its oral formulation TNX-103, which is being developed to treat PH-HFpEF, the most prevalent form of pulmonary hypertension worldwide and an indication with no approved therapies to date.
Average Trading Volume: 363,337
Technical Sentiment Signal: Hold
Current Market Cap: $242.5M
Learn more about TENX stock on TipRanks’ Stock Analysis page.